Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

This study has been completed.
Sponsor:
Information provided by:
Robin, Alan L., M.D.
ClinicalTrials.gov Identifier:
NCT00329095
First received: May 19, 2006
Last updated: May 22, 2006
Last verified: May 2006
  Purpose
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Condition Intervention Phase
Glaucoma
Ocular Hypertension
Drug: travoprost, latanoprost, or bimatoprost
Drug: Additional ocular hypotensive medication
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures

Resource links provided by NLM:


Further study details as provided by Robin, Alan L., M.D.:

Primary Outcome Measures:
  • Compliance.

Estimated Enrollment: 60
Study Start Date: December 2005
Estimated Study Completion Date: April 2006
Detailed Description:
This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Currently using one or two topical ocular hypotensive medications

Exclusion Criteria:

  • Hypersensitivity to any component of medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00329095

Sponsors and Collaborators
Robin, Alan L., M.D.
Investigators
Principal Investigator: Alan L. Robin, MD Alan L. Robin, M.D.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00329095     History of Changes
Other Study ID Numbers: GMED-01
Study First Received: May 19, 2006
Last Updated: May 22, 2006

Keywords provided by Robin, Alan L., M.D.:
Glaucoma
Compliance

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Latanoprost
Antihypertensive Agents
Bimatoprost
Travoprost

ClinicalTrials.gov processed this record on May 22, 2017